

CSR OVERSIGHT AND COMPLIANCE

CSR Governance

Viatris' Board of Directors oversees management's efforts with respect to corporate environmental and social responsibility matters through its Risk Oversight Committee. The CSR function operates as a center of excellence within the Corporate Affairs leadership team. The Head of Corporate Affairs reports directly to the CEO and communicates quarterly with the Viatris Board through the Risk Oversight Committee together with the Head of Corporate Social Responsibility. On an annual basis the Risk Oversight Committee reviews progress with the Head of Corporate Affairs on corporate environmental and social responsibility-related matters that have been discussed with the Viatris Board to confirm the company is tracking its priorities in this area.

The Head of Corporate Social Responsibility drives the strategic and operational development of CSR across the company together with key partners. The global CSR function includes teams in the U.S., Europe and India, with additional partners across other functions.

A multifunctional CSR Advisory Committee comprised of global leaders with a monthly meeting cadence monitors the external landscape, company progress and supports the integration of corporate environmental and social responsibility activities across the organization. Progress on strategic focus areas and execution of relevant tasks rely on a broad and engaged network of functional leaders across the company. Additional structured forums are convened on a monthly to quarterly cadence, addressing areas of focus with regards to CSR and sustainability for specific key functions, such as the Sustainable Sourcing Council and Operations and CSR working group and others, complementing the advisory committee.

Risk Governance and Management

We are committed to operating ethically and with integrity and seek to apply a holistic, enterprise-wide approach to risk management. We are subject to a number of risks inherent in the complex and rapidly changing environment in which we operate including, but not limited to, global operations, environmental and social matters. The company's management and employees implement and administer risk management processes to identify material risks to our business. Management assesses, monitors and manages material risks to our business, all while maintaining flexibility in how we operate. To further embed risk management and compliance into our culture, we implement policies and procedures and train employees on how to comply with them.

Management reports quarterly to the Viatris Board's Risk Oversight Committee regarding enterprise risk, as well as other committees regarding risk-related matters within the scope of their oversight responsibilities. Global Internal Audit and Global Compliance report into the audit and compliance committees of the Viatris Board, respectively.

The company's enterprise risk management (ERM) and business crisis management processes and associated programs are supported by multiple functional areas, including, among others, Global Internal Audit, Global Information Technology, Global Information Security, Global Compliance, CSR, Global EHS, Global Security, Finance, Legal, Quality and Product Safety. Other stakeholders support the company's ERM activities as needed. These programs are designed to support the business and ensure the company is prepared to respond to a variety of events that may adversely impact it, such as unrest/conflicts, legal or regulatory matters, supply disruptions, pandemics and environmental events (including those related to climate change).

By embedding our ERM program into the company's strategic planning process, we seek to optimize our ability to identify risks, while identifying and leveraging opportunities.

How Viatris Considers Price as Part of Our Commitment to Access

At Viatris, we provide an exceptionally broad and diverse portfolio for patients across a broad range of major therapeutic areas, spanning both noncommunicable and infectious diseases. Our global portfolio includes best-in-class, iconic brandname products as well as global key brands and generics, including branded and complex generics. Many of the medicines in our portfolio are not protected by patents and therefore are subject to a general trend of price deflation over time.

As we participate in tender programs or public private partnerships around the globe, we evaluate the price of the generics within our portfolio based on an assessment of patients' need, supply, demand, the cost of manufacturing and the affordability of our products, especially as it relates to the equivalent brand name drug, among other determinants. Other factors considered when pricing our branded portfolio include their value to patients and providers as well as current economic indicators.

Working to ensure that patients across all income levels have access to the medicines we offer means we must carefully evaluate the socioeconomic conditions within each market where Viatris does business while simultaneously sustaining our ability to consistently provide patients with a reliable supply of the quality products they need. We work to provide holistic solutions for governments, NGOs and health systems globally, as we partner to connect more people to products and services.



We conduct periodic enterprise risk assessments to identify key and emerging risks, in which ESG priority issues are considered. For each key and emerging risk identified, we have a process to establish risk ownership. In 2022, we continued to enhance our ERM program in the areas of risk monitoring and reporting, which include the identification of risk elements and risk mitigation activities, along with the identification and tracking of key risk indicators. Corporate environmental and social matters are included in the program given their importance to Viatris' overall sustainability performance and their relevance to key stakeholders. Other areas of elevated focus in 2022 were information security and cyber security.

In connection with its oversight responsibilities, the Compliance Committee of the Viatris Board reviews significant global compliance-related policies relating to pricing and/or commercialization of the company's products and services, among other oversight responsibilities.

Information Security

We have an information security strategy that focuses on the implementation of effective controls, procedures, and training on decreasing risks, increasing information security maturity, improving security capabilities and secure partnership enablement.

Our Information Security organization consists of an internal team of certified subject matter experts in information security risk management, supply chain information security, incident response, access and application security, education and awareness and security operations. The team is supplemented by 24/7/365 managed security service providers that serve as the initial point of contact globally for security monitoring, incident response and vulnerability management. In addition, we require minimum security controls for third parties accessing, processing or storing our information as part of the third-party risk management program. The Viatris leadership team is updated on a quarterly basis and as needed regarding the status of the overall cybersecurity program, emerging external and internal risks and key risk indicators performance. The Risk Oversight Committee receives reports from senior management on data security, cybersecurity and information securityrelated matters on at least a quarterly basis, including with respect to related risks, risk management, and relevant legislative, regulatory and technical developments. The Chief Information Security Officer and Chief Information Officer report bi-annually to the Risk Oversight Committee of the Viatris Board regarding our information security program and performance.

Protections Against Hacking

We run a security monitoring program in partnership with an external managed security service provider. We employ multifactor authentication and certificate-based encryption for all external access and authenticated connections. Vulnerability management and patch management processes are in place to reduce the overall threat landscape. The network is monitored at all times, using industry best practices, tools and processes. Penetration testing is conducted guarterly by internal and third-party resources based on asset risk. Cybersecurity simulations, including tabletop exercises, are executed to test the company's procedures and the internal team's ability to detect, respond and recover in the event of an attack. When first joining Viatris and then annually, employees and contract workers receive training on information security and acceptable use of company computing and information resources. Our standards and policies are reviewed on an annual basis by a third party.

As part of continuing to improve our overall information security capabilities, we focus on addressing all areas of the National Institute for Science and Technology (NIST) Cybersecurity Framework (CSF): Identify, Detect, Protect, Respond and Recovery. Every two years, we conduct a cybersecurity maturity benchmark against the NIST CSF using the Gartner Cybersecurity Controls Assessment tool.

Global Privacy Governance

In response to the growing landscape of global data privacy laws, Viatris is committed to protecting information relating to identified or identifiable natural persons (personal data) collected and processed during the course of business activities. Additionally, Viatris recognizes a separate obligation to the individuals with whom it interacts and who trust the company with their personal data to protect that personal data and keep it secure.

Viatris demonstrates this commitment to data privacy laws and its obligation to individuals with the implementation of a global privacy program. The Viatris Global Privacy program reports regularly to the company's Compliance Committee and is responsible for the development, implementation, maintenance and adherence to the company's policies and procedures and applicable data privacy laws and principles. All company personnel are required to adhere to and comply with these data privacy policies and procedures and with applicable data privacy laws and principles. An internal Global Privacy Governance Document and supporting procedures, materials and training programs provide guidance to employees about how compliance is achieved.

To demonstrate this commitment and obligation transparently, a Viatris Privacy Notice (Privacy Notice) that describes our collection, use, disclosure and retention of personal data is published publicly. The Privacy Notice relates to our websites, apps, services and platforms, and the use of them, our marketing and provision of products and services, our interactions with individuals in person, by phone, or by mail, and otherwise during the operation of our business. The Privacy Notice also explains the ways in which, under applicable laws, an individual can control the processing of their personal data and exercise their rights. Also, there are additional privacy notices and privacy language provided directly to applicable individuals that give information relating to other areas where Personal Data may be collected, used, disclosed or retained by the company such as in clinical trials, safety reporting and during employment with Viatris.

Building sustainable access to medicine

The company monitors, investigates and responds to suspected and/or confirmed personal data incidents as required by applicable data protection laws and in proportion to the nature, extent and sensitivity of the personal data.

Key areas within Global Privacy Governance include, but are not limited to:

- Aligning the company's practices and procedures with all relevant local, national, regional and international laws, regulations and principles;
- Overseeing the revision and negotiation of privacy agreements and privacy terms;
- Privacy and data protection due diligence for third parties, including vendors and HCPs, and in connection with distribution arrangements and acquisitions;
- Ensuring appropriate and compliant responses to an individual's privacy rights requests;
- Employee training;
- Appropriate contact with relevant data protection authorities and handling inquiries and requests for information from same; and
- Investigation of any suspected and/or confirmed incidents.

Cultivating Good Conduct and Compliance

Everyone in the company - and those acting on our behalf - are personally responsible and accountable for the company's reputation and dedication to doing business with integrity. We implement robust policies, procedures and associated training to support that individual responsibility.

Our Global Compliance Organization

The Chief Compliance Officer (CCO) has the operational responsibility to ensure the company's corporate compliance program is effective and robust and directs its day-today implementation. To ensure broad perspectives and independence in the compliance department, the CCO reports to the Viatris Board's Compliance Committee and the CEO. The Compliance Committee makes recommendations to the Viatris Board and/or oversees the development, implementation, maintenance and monitoring of the corporate compliance program, the Code of Business Conduct and Ethics, and significant related global policies designed to support and promote compliance with company requirements, laws and regulations. This includes topics such as Anti-Corruption and Fair Competition, which are covered within the Code of Business Conduct and Ethics.

The company's Code of Business Conduct and Ethics outlines guiding principles on how employees and those working on our behalf must conduct themselves. It also informs on policies and standards while providing highlevel guidance on critical areas of the company's business operations. The compliance department is organized by operating regions and global centers of excellence. The compliance department and the Global Compliance Program are structured in a manner consistent with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG) Resource Guide for Measuring Compliance Program Effectiveness.

A direct report to the CCO leads three global centers of excellence (COEs) that are anchored by our Global Compliance Service Hub and that support the company's global operating regions and business. A senior compliance leader manages each respective center of excellence, which focuses on policies, training and communications, risk assessment and monitoring, due diligence and investigations.

Our compliance framework covers the following components and focus areas:

- Interactions with the Healthcare Community and Organizations
- Raising Concerns
- Operational Compliance
- Fraud and Corruption
- Fair Competition, Pricing, and Anti-trust

- Corporate and Securities Laws
- Fair Employment and Data Privacy Practices

To further reinforce our commitment to compliance, in 2022 we:

- Continued to harmonize compliance-related topics into a unified policy landscape for Viatris, including launching new Business Standards for Vendors and Agents on anti-corruption and fair competition;
- Expanded our Global Compliance Risk Assessment and Monitoring Program into additional countries and furthered our data analytic capabilities; and
- Established a new Global Compliance Governance Document (considered as an annotated Code of Business Conduct and Ethics to guide Viatris employees in acting with integrity).

We have a Global Compliance Service Hub in India, which includes the following key elements:

- Enhanced management of Trade Control Risk
- Mergers and Acquisitions Due Diligence under the direction of global leadership
- Maintain system for Transparency Reporting

Viatris.com features the following compliance documents available to the public:

- Code of Business Conduct and Ethics
- Global Anti-Bribery and Anti-Corruption
 Business Standards for Vendors and Agents
- Global Anti-Corruption Policy Summary
- Global Antitrust and Fair Competition Policy
 Summary
- Global Fair Competition and Antitrust Business Standards for Vendors and Agents
- Standards for Interactions with Healthcare Professionals ("Standards") Policy Summary





The compliance department oversees the development, maintenance and recordkeeping of general and administrative global policies and procedures and performs various periodic and needs-based operational audits throughout the year, often in conjunction with Internal Audit. In 2022, we launched our Compliance Champion Series which features colleagues from a different region each quarter, focusing on various functions and business areas to explain how the compliance team has impacted their work and enabled them to make an Impact via Integrity. Looking forward, we seek to further build awareness and transparency among stakeholders about compliance, including digital assets and our communications materials.

Identifying and Managing Compliance-Related Risks

We have several processes and procedures to monitor and assess emerging risk areas relevant to Viatris, including a risk assessment process that provides comprehensive insights into compliance risks depending on a market's geographic footprint. Global Compliance collaborates with Global Internal Audit (GIA) to identify compliance-related risks (including anti-corruption) and local affiliates to be audited and supports GIA in their reviews. GIA evaluates geographic risks and other outputs from our ERM program to identify potential areas over which it will perform audits.

Monitoring is a Compliance-led initiative designed to support regional compliance teams to identify, analyze and address non-compliance associated in each market. The objective is to highlight potential deviations and provide guidance on focus areas and remedial action to regional compliance.

Topics covered by monitoring include data analytics conducted by the center of excellence to identify potential deviations related to HCP interactions, live monitoring and ride-alongs to observe potential deviations at a companyorganized or sponsored event or field force activities, and focused in-market reviews leveraging data monitoring. In 2022, Viatris employed a third party to conduct an effectiveness assessment review that resulted in no major findings.

- The assessment concluded that the Viatris Compliance department has implemented significant enhancements to all areas of the program since the forming of Viatris.
- In assessing and comparing Viatris' Compliance Program against industry regulatory requirements and leading practices, this third party concluded the Compliance Program is meeting obligations to detect, prevent and mitigate compliance risk.

Management of Suspected Incidents

We take all allegations of conduct that is contrary to company policy or applicable law seriously. The Investigations Center of Excellence (Investigations COE) exists to ensure that we discover and respond to potential violations of law and/or company policies. Taking each matter seriously allows us to protect the company. Viatris' Investigations COE allows for a fair, objective, independent review of all relevant facts.

When an allegation is received, a preliminary analysis is promptly conducted to determine the most appropriate review. Regional Investigation Committees are established for each business region to ensure cross functional alignment and communication among key stakeholders that are involved in internal compliance investigations.

The committee aligns on outcome and closure which may include discipline, where appropriate, and implementation of corrective and preventive actions such as training, monitoring or other improvements. Compliance matters and metrics are tracked and shared with management and the Compliance Committee of the Viatris Board on a regular cadence.

If any Viatris colleague has knowledge or suspects a violation of accounting standards or internal controls, they may report such concerns directly to the Audit Committee in addition to the reporting lines described in the Global Compliance Governance Document and the Viatris Code of Business Conduct and Ethics. Viatris' Compliance Line is described below and available on <u>Viatris' website</u>.

Looking forward, we plan to expand the Risk Assessment Program to additional European and Emerging Market countries and make the risk assessment an annual exercise.

Training and Education

We require and provide dedicated training on anti-corruption, fair competition and the company's Standards for Interactions with HCPs for employees with relevant job responsibilities. We also require specific training courses for individuals based on their functions. Examples include:

- · Vendors who may interact with government officials on our behalf also receive anticorruption training.
- Depending on their role, part-time employees and contractors are required to take subsets of the trainings listed above.
- Employees who deal directly with the government receive additional, focused training related to Standards for Interactions with HCPs from their local Compliance partner(s).



In addition to comprehensive training in relevant areas in which an employee may work, we require employees to complete regular trainings in regard to the Code of Business Conduct and Ethics, Fair Competition and Anti-Corruption, among other topics, and track completion rates. In 2022, the completion rate for Code of Business Conduct and Ethics training was 95%.

Training is provided for employees regarding bribery, corruption, facilitation payments and areas of increased risk. The training also guides employees on what constitutes acceptable behavior and how to seek support when questions arise.

In 2022, we launched enhanced compliance training modules covering the following topics: Anti-Corruption, Fair Competition and the Code of Business Conduct and Ethics, with translated versions to be made available in a variety of local languages in 2023. Our new Code of Business Conduct and Ethics training module included a new supplementary Compliance Certification for Management intended to provide an additional mechanism to help reinforce key compliance program elements.

Fighting Corruption and Promoting Fair Competition

The company's anti-corruption program is based on the elements of the U.S. Department of Justice (DOJ) and Securities and Exchange Commission (SEC) Resource Guide to the U.S. Foreign Corrupt Practices Act; the U.K. Ministry of Justice Bribery Act 2010 Guidance; and the Organisation for Economic Cooperation and Development's Good Practice Guidance on Internal Controls, Ethics and Compliance, as well as the local laws where we operate. Key elements include:

- Our anti-corruption policy requirements set out in our Global Compliance Governance Document strictly forbid bribery and corruption in any form anywhere we do business.
- The policy defines bribery and corruption, including facilitation payments, which are strictly prohibited even where permitted under local law.
- We have monitoring and auditing procedures in place to identify and deter such payments.
- We reassess our anti-corruption program periodically and make enhancements as warranted. Training is provided for employees regarding bribery, corruption, facilitation payments and areas of increased risk. The training also guides employees on what constitutes acceptable behavior and how to seek support when questions arise. We also monitor cases of suspected conflict of interest. Each identified case is investigated, and if concerns remain after the investigation, appropriate actions are taken.

We provide several options for personnel to submit concerns or seek guidance: either online or via telephone, mail or email. Colleagues can also reach out to their manager, specific departments, their local compliance support or use the Compliance Line.

As part of the company's ERM program, GIA assesses anti-corruption and anti-fraud management over entities throughout the world from a corruption risk perspective. Size (the number of people and sales volume) and a country's ranking in the Transparency International Corruption Perception Index (CPI) are key to informing the potential risk profile of an entity. Entities identified as being in a higher-risk environment along with those of strategic importance to the company are a particular focus. Further, we monitor business activities that are deemed an elevated risk — such as government officials and HCP interactions through established internal processes and controls. Anti-corruption language is included in our contracts, as applicable. We also have a process to train business partners who interact with government officials on the company's behalf in our anticorruption policy requirements and procedures.

We provide training on relevant compliance policy requirements to contractors, external temporary workers and/or distributors on an as-needed basis depending on their function and the services they are to provide to Viatris.

Ensuring Good Conduct in External Partnerships

External partners sometimes act as intermediaries on our behalf or in settings where special skills or expertise are required. Given their role, it's essential these partners comply with the company's ethical and anti-corruption standards and act with good judgment.

The compliance department identifies business partner categories that may carry higher inherent corruption and/ or reputational risk. These high-risk business partners, noted during the business contract drafting and approval process, are subject to a risk review based on a robust due diligence process including investigation and clarification of discovered legal, civil and reputational allegations or convictions.

Viatris has a third-party due diligence program that is global in scope, managed by a dedicated team. Per its scope, due diligence reviews must be performed whenever Viatris enters into certain potentially high-risk contractual agreements with third parties. The process involves an assessment of any issues (environmental, legal, social or otherwise) that have been brought to light in the public sphere regarding a supplier or any other third party.



Our program is to subject potentially highrisk business partners to a due diligence review and annual monitoring.

Further, the due diligence team in collaboration with the COE of Risk Assessment and Monitoring and Global Trade Control also manages third parties in relation to:

- Business development;
- Mergers and acquisitions;
- Divestitures;
- Other strategically important deals; and
- Restricted party screening under the global trade control procedure.

In 2022, we enhanced awareness of our Compliance Line and translated the web intake site into 10 key business languages for ease of reporting.

The compliance line is promoted on <u>Viatris.com</u>.



Reporting Compliance Concerns

We encourage open communication and provide a variety of channels for reporting potential compliance violations. Employees are encouraged to discuss compliance concerns with their supervisor, Human Relations, Legal or Compliance. They also can use the company's Compliance Line, which is operated by an external party. This is a grievance mechanism where employees should feel safe to report. The Compliance Line is available 24/7 and permits anonymous reports in countries in local languages, where permitted by law. Viatris strictly prohibits retaliation relating to any reports made in good faith. The Compliance Line is available both on our intranet and external website.

A Robust Procedure to Manage Reports

For investigating, resolving and remediating reported events, our Global Policy on Reporting and Investigating Compliance Related Matters requires thorough, timely and impartial investigation of reported concerns in coordination with the Human Relations team as well as Legal and other functions as appropriate and fair and consistent disciplinary measures when appropriate. Our policy requirements on reporting and investigating matters were assessed for updates in 2022 to incorporate specific EU Whistleblower Directive provisions.

The policy is available to all employees on the company's intranet. Every effort will be made to keep reports of Compliance-Related Matters (CRMs) and Other Reported Matters (ORMs) confidential to the extent possible, consistent with the need to conduct an adequate investigation and in accordance with any applicable local law. Compliance and its partners seek to maintain confidentiality throughout the investigation process and to help ensure that good faith reporters do not suffer negative employment actions as a result of their allegations. If any Viatris colleague believes that they or other Viatris colleagues have been retaliated against for reporting a matter pursuant to the Governance Document and the Viatris Code of Business Conduct and Ethics, they should immediately report such perceived retaliation.

Responsible Marketing and Promotion

Our colleagues often interact with members of the healthcare community as part of their efforts to educate them on the appropriate use and efficacy of the company's products. These interactions are important and fundamental to increasing patient access but may bring elevated risk. Our Standards for Interactions with Healthcare Professionals instruct employees on proper behavior when engaging with HCPs. The standards are grounded in companywide standards and take into consideration local laws and regulations. Any member of our workforce who interacts with HCPs is trained on the standards and is required to comply with them. Additionally, employees are trained in the company's Code of Business Conduct and Ethics, which also addresses interactions with healthcare professionals. An updated summary of our Standards for Interactions with Healthcare Professionals is available on the Viatris website.

We have well established global, regional and local policies and procedures that inform employees on appropriate interactions with the healthcare community and requirements pertaining to drug promotion and ethical marketing. Risk assessments, monitoring and employee training are key components of each. We strive to comply with regulations and adhere to ethical standards set forth by the company and industry associations.



The Global Policy on Promotional Materials requires the establishment of local procedures to ensure that all promotional materials and other commercial communications are reviewed and approved internally by appropriate subject matter experts.

- The goal of the local review procedures implemented under the policy is to ensure that all materials and communications intended for promotional or commercial purposes are accurate, truthful, medically and scientifically sound, not misleading and compliant with all applicable marketing, legal, regulatory and medical requirements and company policies.
- These local procedures include clear review processes, risk assessments and compliance monitoring as part of the company's compliance program and enterprise risk management.

Respecting Human Rights

As a participant in the UN Global Compact, we recognize our responsibility to respect human rights and further to support government responsibility to protect human rights within and beyond our own operations. We do so through our core business in building sustainable access to medicines and supporting equity in access to treatment. We also do this in how we conduct ourselves in our dealings with partners. We are committed to the Ten Principles of the UN Global Compact and respect the International Bill of Human Rights and the Fundamental Conventions of the International Labour Organization.

The company's global policies and associated procedures, employee and partner training and due diligence procedures are the foundation of our work to mitigate the risk of humanrights violations.

Engaging in Political Activity Responsibly

As part of advocating for sustainable access to medicine and holistic solutions for more resilient healthcare systems, we educate stakeholders on complex topics related to the highly regulated pharmaceutical industry. As a global healthcare Topics relevant to human rights are addressed through a variety of company policies and procedures, including our Code of Business Conduct and Ethics, Supplier Code of Conduct, Policy Statement Regarding Slavery and Human Trafficking, Global Policy on Combatting Human Trafficking in Persons, Policy on Diversity and Inclusion and the Global Policy Prohibiting Discrimination, Harassment and Retaliation as well as the companywide EHS program, Viatris' Environment, Health and Safety and Business Resiliency program and third-party due diligence program.

Topics covered include:

- Freedom of association
- Prohibition of trafficking of persons
- Prohibition of forced and child labor
- Nondiscrimination
- Handling of identity and immigration documents
- Wages
- Working hours
- Safety in the workplace
- Preventing harassment
- Recruitment practices

company, we seek to mitigate the risk of unintended negative consequences for patients from even the most well-intended policies.

In accordance with relevant laws and regulations, Viatris may support political candidates and organizations of various political parties, directly or through trade associations, in support of public policies that align with Viatris' mission and policy objectives. Among other areas of interest, we support efforts that contribute to pharmaceutical safety and innovation to further our mission in providing patients access to high-quality medicine.

All political contributions are required to be made in accordance with relevant local laws, reflect Viatris' interests and are independent of the personal political preferences of any Viatris personnel.

Only to the extent allowed by law may Viatris directly contribute to political candidates and political organizations. This is relevant primarily for Viatris' U.S. subsidiaries and Viatris' U.S. Political Action Committee (ViaPAC), a voluntary, nonpartisan, employee-run committee. The Viatris Board's Compliance Committee oversees company global policies and procedures for corporate political and lobbying expenditures. A report of these expenditures, along with certain U.S. trade association affiliations is made available on our website. Viatris' policy governing political contributions also is available on Viatris.com. Within the U.S., that includes filing relevant lobbying and political contribution reports in accordance with the U.S. Lobbying Disclosure Act.

Those reports can be found on the U.S. Senate Office of Public Records website or the U.S. House of Representatives Office of the Clerk website. Viatris is also required to comply with any laws that govern its lobbying and advocacy efforts generally.

Honoring Our Commitment as a Publicly Traded Company

Viatris Inc. is a publicly traded company listed on NASDAQ and incorporated in Delaware. The Viatris Board of Directors is responsible for oversight of the company and its management. Viatris' board has established seven committees, each of which operates pursuant to a written charter. Certain directors' duties, rights and responsibilities are detailed in the company's Certificate of Incorporation, Bylaws and committee charters, among other governance documents. Viatris is subject to applicable rules, regulations and/or listing standards of the U.S. Securities and Exchange Commission, NASDAQ and the U.S. State of Delaware General Corporation Law, among other requirements.